Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Daito Pharmaceutical Co., Ltd. ( (JP:4577) ) has issued an update.
Daito Pharmaceutical has repurchased 225,600 shares of its common stock for approximately 303 million yen via market purchases on the Tokyo Stock Exchange during January 2026, under the authority granted by its Articles of Incorporation and Japan’s Companies Act. This latest transaction brings the cumulative buyback under the October 2025 board authorization to 597,200 shares for about 771 million yen, signaling ongoing capital management efforts that may support shareholder value and optimize the company’s capital structure during the authorized repurchase period through May 2026.
The most recent analyst rating on (JP:4577) stock is a Hold with a Yen1398.00 price target. To see the full list of analyst forecasts on Daito Pharmaceutical Co., Ltd. stock, see the JP:4577 Stock Forecast page.
More about Daito Pharmaceutical Co., Ltd.
Daito Pharmaceutical Co., Ltd. is a Japan-based pharmaceutical company listed on the Prime Market of the Tokyo Stock Exchange, focused on developing, manufacturing, and selling pharmaceutical products.
Average Trading Volume: 72,511
Technical Sentiment Signal: Buy
Current Market Cap: Yen40.14B
Find detailed analytics on 4577 stock on TipRanks’ Stock Analysis page.